| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
MING YAO; Lin C.-W.; Lin H.-H.; Huang S.-Y.; Chou S.-J.; Chou W.-C.; Tsay W.; Chen C.-Y.; Hou H.-A.; Chen Y.-C.; Lu H.-Y.; Wu S.-J.; Tang J.-L.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution
|
Lin C.-C.; Hou H.-A.; Chou W.-C.; Kuo Y.-Y.; Wu S.-J.; Liu C.-Y.; Chen C.-Y.; Tseng M.-H.; Huang C.-F.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; JIH-LUH TANG; Yao M.; Huang S.-Y.; Hsu S.-C.; Ko B.-S.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
SHANG-YI HUANG; Lin C.-W.; Lin H.-H.; Yao M.; Tang J.-L.; Wu S.-J.; Chen Y.-C.; Lu H.-Y.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Tsay W.; Chou S.-J.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients
|
Huang S.-Y.; Kuo Y.-Y.; Li C.-C.; Tang J.-L.; Yao M.; Liu C.-W.; Liu M.-C.; Lee F.-Y.; Chou W.-C.; Yang Y.-T.; Hou H.-A.; Liu C.-Y.; Lin C.-C.; HWEI-FANG TIEN; Chen Y.-C.; Tsay W.; Wu S.-J.; Lin C.-T.; Hsu S.-C.; Ko B.-S.; Chen C.-Y. |
| 國立臺灣大學 |
2013 |
Clinical impact of pre- and post-transplant residual disease status detected by multidimensional flow cytometry in 120 adult patients with acute leukaemia
|
Li, C. C.; Tang, J. L.; Lin, C. T.; Yao, M.; Ko, B. S.; Wu, S. J.; Huang, S. Y.; Liu, J. H.; Chou, W. C.; Hou, H. A.; Tien, H. F.; Loken, M. R.; 姚明; 柯博升; 田蕙芬; 黃聖懿; 吳尚儒; 唐季祿; 周文堅; 侯信安 |
| 國立臺灣大學 |
2013 |
Allogeneic stem cell transplantation from unrelated-mismatched/familial-mismatched donors, which would be better?
|
Liao, X. W.; Lin, C. T.; Yao, M.; Li, C. C.; Ko, B. S.; Lu, M. Y.; Lin, K. H.; Jou, S. T.; Wu, S. J.; Lin, D. T.; Yang, Y. L.; Huang, S. Y.; Hou, H. A.; Liu, J. H.; Tang, J. L.; 林東燦; 姚明; 周獻堂; 柯博升; 盧孟佑; 黃聖懿; 吳尚儒; 林凱信; 唐季祿; 楊永立; 侯信安 |
| 臺大學術典藏 |
2013 |
Anti-inflammatory effect of sophoraflavanone G isolated from Sophora flavescens in lipopolysaccharide-stimulated mouse macrophages
|
Liou C.-J.; Wu S.-J.; WEI-TIEN CHANG; Xu P.-Y.; Huang Y.-L.; Lin C.-F.; Huang W.-C.; Wun Z.-Y.; Liou C.-J.;Wu S.-J.;WEI-TIEN CHANG;Xu P.-Y.;Huang Y.-L.;Huang W.-C.;Lin C.-F.;Wun Z.-Y. |
| 臺大學術典藏 |
2013 |
Phloretin and phlorizin promote lipolysis and inhibit inflammation in mouse 3T3-L1 cells and in macrophage-adipocyte co-cultures
|
Liou C.-J.;Ting N.-C.;Xu P.-Y.;Wu S.-J.;WEI-TIEN CHANG;Huang W.-C.; Huang W.-C.; WEI-TIEN CHANG; Wu S.-J.; Xu P.-Y.; Ting N.-C.; Liou C.-J. |
| 臺大學術典藏 |
2013 |
Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence - Clinical implication and comparison between the West and the East
|
Hou H.-A.; Lee F.-Y.; Liu M.-C.; Lin C.-T.; Huang S.-Y.; Wu S.-J.; Chen C.-Y.; Ko B.-S.; Chou W.-C.; Yao M.; Tang J.-L.; Tsay W.; HWEI-FANG TIEN |
| 臺大學術典藏 |
2013 |
Improving but Inferior Survival in Patients with Chronic Lymphocytic Leukemia in Taiwan: A Population-Based Study, 1990-2004
|
Wu S.-J.; Chiang C.-J.; Lin C.-T.; HWEI-FANG TIEN; Lai M.-S. |
| 臺大學術典藏 |
2013 |
Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia
|
Lai Y.-J.; Jhuang J.-Y.; Liu C.-Y.; Lee M.-C.; Hou H.-A.; Cheng C.-L.; HWEI-FANG TIEN; Lin C.-W.; Chen H.-Y.; Liu F.-T.; Chou W.-C.; Chen C.-Y.; Tang J.-L.; Yao M.; Huang S.-Y.; Ko B.-S.; Wu S.-J.; Tsay W. |
| 臺大學術典藏 |
2013 |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Lin C.-T.; Wu S.-J.; Tang J.-L.; MING YAO; Chou W.-C.; Chen C.-Y.; Liu C.-W.; Hou H.-A.; Liu M.-C.; Lee F.-Y.; Lai Y.-J.; Huang C.-F.; Tseng M.-H.; Li L.-Y.; Kuo Y.-Y.; Tien H.-F.; Huang S.-Y.; Ko B.-S.; Tsay W. |
| 臺大學術典藏 |
2013 |
Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia
|
Lai Y.-J.; Jhuang J.-Y.; Liu C.-Y.; Lee M.-C.; Hou H.-A.; Cheng C.-L.; Tien H.-F.; Tsay W.; Wu S.-J.; Lin C.-W.; Chen H.-Y.; Liu F.-T.; Chou W.-C.; Chen C.-Y.; Tang J.-L.; MING YAO; Huang S.-Y.; Ko B.-S. |
| 臺大學術典藏 |
2013 |
Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia
|
Cheng C.-L.; Hou H.-A.; Lee M.-C.; Liu C.-Y.; Jhuang J.-Y.; Lai Y.-J.; Lin C.-W.; Chen H.-Y.; Liu F.-T.; Chou W.-C.; Chen C.-Y.; JIH-LUH TANG; Yao M.; Huang S.-Y.; Ko B.-S.; Wu S.-J.; Tsay W.; Tien H.-F. |
| 臺大學術典藏 |
2013 |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Tang J.-L.; Wu S.-J.; Ko B.-S.; Tsay W.; Tien H.-F.; Lin C.-T.; Kuo Y.-Y.; Li L.-Y.; Tseng M.-H.; Huang C.-F.; Lai Y.-J.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Yao M.; SHANG-YI HUANG |
| 臺大學術典藏 |
2013 |
Anti-inflammatory effect of sophoraflavanone G isolated from Sophora flavescens in lipopolysaccharide-stimulated mouse macrophages
|
Wun Z.-Y.; Lin C.-F.; Huang W.-C.; Huang Y.-L.; Xu P.-Y.; WEI-TIEN CHANG; Wu S.-J.; Liou C.-J. |
| 淡江大學 |
2012-07 |
Optimal warranty policy for a Pareto distributed products based on progressive censored sample
|
Karadayi, N. ; AkdoÄan, Y. ; KuÅ, C. ; Wu, S.-J. |
| 淡江大學 |
2012-07 |
Optimal progressive group censoring scheme under cost considerations for Pareto distribution
|
Kuş, C.; Akdoğan, Y.; Wu, S.-J. |
| 臺大學術典藏 |
2012 |
DNMT3A mutations in acute myeloid leukemia: Stability during disease evolution and clinical implications
|
Liu C.-Y.; Chou W.-C.; Kuo Y.-Y.; Hou H.-A.; HWEI-FANG TIEN; Chen Y.-C.; Tsay W.; Wu S.-J.; Hsu S.-C.; Ko B.-S.; Huang S.-Y.; Yao M.; Tang J.-L.; Liu C.-W.; Lee F.-Y.; Liu M.-C.; Huang C.-F.; Chiang Y.-C.; Tseng M.-H.; Lin L.-I.; Lee M.C.; Chen C.-Y. |
| 臺大學術典藏 |
2012 |
The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution
|
Hou H.-A.; Wu S.-J.; Kuo Y.-Y.; Ko B.-S.; Huang S.-Y.; Chou W.-C.; MING YAO; Chen C.-Y.; Lin C.-T.; Liu C.-W.; Lee F.-Y.; Liu M.-C.; Huang C.-F.; Li Y.; Tseng M.-H.; Tsay W.; Tien H.-F.; Tang J.-L. |
| 臺大學術典藏 |
2012 |
DNMT3A mutations in acute myeloid leukemia: Stability during disease evolution and clinical implications
|
Lee M.C.; Liu C.-Y.; Chou W.-C.; Kuo Y.-Y.; Hou H.-A.; MING YAO; Tang J.-L.; Liu M.-C.; Liu C.-W.; Lee F.-Y.; Chiang Y.-C.; Huang C.-F.; Tseng M.-H.; Chen C.-Y.; Lin L.-I.; Tien H.-F.; Chen Y.-C.; Tsay W.; Wu S.-J.; Huang S.-Y.; Ko B.-S.; Hsu S.-C. |
| 臺大學術典藏 |
2011 |
Antiproliferative activity of Cinnamomum cassia constituents and effects of pifithrin-alpha on their apoptotic signaling pathways in Hep G2 cells
|
Wu, S.-J.; Ng, L.-T.; LEAN-TEIK HUANG |
| 臺大學術典藏 |
2011 |
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
|
Ko B.-S.; Lee M.-C.; Kuo Y.-Y.; Chen C.-Y.; Hou H.-A.; Liu C.-Y.; Chou S.-C.; Chou W.-C.; HWEI-FANG TIEN; Tang J.-L.; Yao M.; Tsay W.; Wu S.-J.; Huang S.-Y.; Hsu S.-C.; Chen Y.-C.; Chang Y.-C.; Kuo Y.-Y.; Kuo K.-T.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Tseng M.-H.; Huang C.-F. |
| 臺大學術典藏 |
2011 |
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
|
Liu C.-Y.; SHENG-CHIEH CHOU; Chou W.-C.; Tien H.-F.; Huang C.-F.; Tseng M.-H.; Liu C.-W.; Liu M.-C.; Lee F.-Y.; Kuo K.-T.; Kuo Y.-Y.; Chang Y.-C.; Chen Y.-C.; Hsu S.-C.; Chen C.-Y.; Hou H.-A.; Kuo Y.-Y.; Lee M.-C.; Ko B.-S.; Tang J.-L.; Yao M.; Tsay W.; Wu S.-J.; Huang S.-Y. |
| 臺大學術典藏 |
2011 |
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
|
Tang J.-L.; Ko B.-S.; Kuo Y.-Y.; Lee M.-C.; Hou H.-A.; Chen C.-Y.; Liu C.-Y.; Chou S.-C.; Chou W.-C.; Huang C.-F.; Tseng M.-H.; Liu M.-C.; Liu C.-W.; Lee F.-Y.; Kuo K.-T.; Kuo Y.-Y.; MING YAO; Tsay W.; Wu S.-J.; Huang S.-Y.; Hsu S.-C.; Chen Y.-C.; Chang Y.-C.; Tien H.-F. |
